ARTICLE | Clinical News
RSD1235: Began Phase I trial
April 16, 2001 7:00 AM UTC
Nortran Pharmaceuticals Inc. (TSE:NRT; NTRDF), Vancouver, B.C. Product: RSD1235 Business: Cardiovascular, Drug delivery Therapeutic category: Ion channel modulation Target: Ion channels Description: I...